

# Muriel D David

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7847273/publications.pdf>

Version: 2024-02-01

27  
papers

2,357  
citations

331670

21  
h-index

526287

27  
g-index

27  
all docs

27  
docs citations

27  
times ranked

3960  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phosphorylation of ARHGAP19 by CDK1 and ROCK regulates its subcellular localization and function during mitosis. <i>Journal of Cell Science</i> , 2018, 131, .	2.0	9
2	Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 300-305.	2.8	292
3	Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. <i>Nature Medicine</i> , 2018, 24, 1167-1177.	30.7	157
4	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations. <i>Cancer Discovery</i> , 2017, 7, 478-493.	9.4	350
5	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. <i>Blood</i> , 2017, 130, 732-741.	1.4	300
6	Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1022, 290-297.	2.3	30
7	Familial hematological malignancies: new IDH2 mutation. <i>Annals of Hematology</i> , 2016, 95, 1943-1947.	1.8	7
8	A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a <i>D<sup>2</sup>Ch</i> hydroxyglutaric aciduria type II mouse model. <i>Journal of Inherited Metabolic Disease</i> , 2016, 39, 807-820.	3.6	11
9	The RhoGAP ARHGAP19 controls cytokinesis and chromosome segregation in T lymphocytes. <i>Journal of Cell Science</i> , 2014, 127, 400-10.	2.0	23
10	Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice. <i>Leukemia</i> , 2014, 28, 1343-1346.	7.2	18
11	Suppressor of cytokine signaling 1 modulates invasion and metastatic potential of colorectal cancer cells. <i>Molecular Oncology</i> , 2014, 8, 942-955.	4.6	30
12	AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo. <i>Blood</i> , 2014, 124, 3734-3734.	1.4	38
13	AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model. <i>Blood</i> , 2014, 124, 3735-3735.	1.4	18
14	Cell cycle regulation of Rho signaling pathways. <i>Cell Cycle</i> , 2012, 11, 3003-3010.	2.6	76
15	Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors. <i>Cancer Research</i> , 2008, 68, 9601-9607.	0.9	166
16	Epigenetic Control of the Immune Escape Mechanisms in Malignant Carcinomas. <i>Molecular and Cellular Biology</i> , 2007, 27, 7886-7894.	2.3	69
17	Distinct Structural Features of Caprin-1 Mediate Its Interaction with G3BP-1 and Its Induction of Phosphorylation of Eukaryotic Translation Initiation Factor 2 $\epsilon$ , Entry to Cytoplasmic Stress Granules, and Selective Interaction with a Subset of mRNAs. <i>Molecular and Cellular Biology</i> , 2007, 27, 2324-2342.	2.3	213
18	Identification of Mechanisms Underlying Transporter Associated with Antigen Processing Deficiency in Metastatic Murine Carcinomas. <i>Cancer Research</i> , 2005, 65, 7485-7492.	0.9	27

#	ARTICLE	IF	CITATIONS
19	Pure Lipopolysaccharide or Synthetic Lipid A Induces Activation of p21Ras in Primary Macrophages through a Pathway Dependent on Src Family Kinases and PI3K. <i>Journal of Immunology</i> , 2005, 175, 8236-8241.	0.8	30
20	Absence of Caprin-1 Results in Defects in Cellular Proliferation. <i>Journal of Immunology</i> , 2005, 175, 4274-4282.	0.8	60
21	Distinct Mechanisms Determine the Patterns of Differential Activation of H-Ras, N-Ras, K-Ras 4B, and M-Ras by Receptors for Growth Factors or Antigen. <i>Molecular and Cellular Biology</i> , 2004, 24, 6311-6323.	2.3	65
22	GILZ, a new target for the transcription factor FoxO3, protects T lymphocytes from interleukin-2 withdrawal-induced apoptosis. <i>Blood</i> , 2004, 104, 215-223.	1.4	139
23	Functional characterization of IL-13 receptor $\beta$ 2 gene promoter: a critical role of the transcription factor STAT6 for regulated expression. <i>Oncogene</i> , 2003, 22, 3386-3394.	5.9	37
24	TNF $\alpha$ Potentiates IL-4/IL-13-Induced IL-13R $\beta$ 2 Expression. <i>Annals of the New York Academy of Sciences</i> , 2002, 973, 207-209.	3.8	9
25	Induction of the IL-13 receptor $\beta$ 2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways. <i>Oncogene</i> , 2001, 20, 6660-6668.	5.9	94
26	The glucocorticoid receptor and STAT6 physically and functionally interact in T-lymphocytes. <i>FEBS Letters</i> , 2000, 487, 229-233.	2.8	55
27	Binding of IL-4 to the IL-13R $\beta$ 1/IL-4R $\alpha$ receptor complex leads to STAT3 phosphorylation but not to its nuclear translocation. <i>FEBS Letters</i> , 1999, 464, 91-96.	2.8	34